<DOC>
	<DOCNO>NCT00900445</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn affect body mass index way anticancer drug work body . It may also help doctor predict patient respond treatment . PURPOSE : This clinical trial study body mass index young patient receive prednisone/prednisolone , vincristine , daunorubicin , pegaspargase high-risk acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Studying Body Mass Index Younger Patients Who Are Receiving Treatment High-Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To compare pharmacokinetics prednisone/prednisolone , vincristine , daunorubicin hydrochloride among obese , middle-weight , underweight child age 10 less 20 year age undergoing induction therapy high-risk acute lymphoblastic leukemia . - To examine relationship parameter response status define early response induction failure . OUTLINE : This multicenter study . Patients stratify accord body mass index ( BMI ) ( ≥ 95^th percentile [ obese ] v 10^th 95^th percentile [ normal risk overweight ] v ≤ 10^th percentile [ underweight ] ) . Patients receive anticancer therapy prescribe treat clinician . Patients receive prednisone/prednisolone orally twice either day 1 day 8 . Patients also receive daunorubicin hydrochloride IV 30 minute vincristine IV day . Blood sample obtain either day 1 day 8** induction therapy pharmacokinetic analysis prednisone , daunorubicin hydrochloride , vincristine activity level . Blood sample analyze via high-performance liquid chromatography ( HPLC ) , ultrafiltration , Nessler reaction , ELISA , liquid chromatography use reverse-phase chromatography , fluorescent detection , solid-phase extraction . Demographic information , include ethnicity , also collect . Weight height record diagnosis day pharmacokinetic assessment vincristine , prednisone , daunorubicin hydrochloride begin . NOTE : **Patients sample day 8 induction therapy receive intravenous corticosteroid therapy first week induction must receive least six oral prednisone/prednisolone dose prior morning prednisone/prednisolone dose day 8 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia Must assign receive prednisone/prednisolone , vincristine , daunorubicin induction treatment dose schedule per current COG AALL0232 protocol Prior registration onto COG protocol require Must meet 1 follow criterion : Obese ( define body mass index [ BMI ] ≥ 95^th percentile ) Normal weight risk overweight ( define BMI 10^th 95^th percentile ) Underweight ( define ≤ 10^th percentile ) PATIENT CHARACTERISTICS : Able take either prednisone prednisolone mouth day 1 8 induction therapy Not pregnant Negative pregnancy test AST/ALT &lt; 5 time upper limit normal ( ULN ) Total bilirubin ( conjugate + unconjugated ) &lt; 1.5 mg/dL Creatinine ≤ 1.5 time ULN No known malabsorption syndrome PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior concurrent medication food know potential alter pharmacokinetics drug study include follow Grapefruit , tangelo , juice fruit Hypericum perforatum ( St. John 's wort ) Anticonvulsants Carbamazepine Oxcarbazepine Phenytoin Phenobarbital Primidone Azole antifungal agent include : Ketoconazole Fluconazole Itraconazole Voriconazole Macrolide antibiotic Erythromycin Clarithromycin Isoniazid Rifampin Verapamil Diltiazem</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>